Table 3.
Factors affecting progression-free survival after treatment
| Group | Subgroup | n | Median PFS (months) | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|---|---|
|
|
|
||||||
| HR (95%CI) | P | HR (95% CI) | P | ||||
| Age (years) | ≤60 | 225 | 7.4 | 1.0 | 0.131 | ||
| >60 | 230 | 6.5 | 1.2 (0.9-1.5) | ||||
| Sex | Male | 350 | 6.7 | 1.0 | 0.05 | 0.8 (0.6-1.8) | 0.331 |
| Female | 105 | 6.8 | 0.7 (0.6-1.0) | ||||
| Education | Up to primary level | 179 | 6.1 | 1.0 | 0.293 | ||
| Above primary level | 196 | 7.3 | 0.9 (0.7-1.1) | ||||
| NSCLC pathology | SCC | 125 | 6.8 | 1.0 | |||
| ADC | 244 | 7.3 | 0.8 (0.6-1.1) | 0.196 | |||
| NSCLC (NOS) | 86 | 4.7 | 1.0 (0.7-1.5) | 0.805 | |||
| ECOG | 0,1 | 220 | 8.6 | 1.0 | <0.001 | 1.9 (1.5-2.4) | <0.001 |
| 2,3,4 | 173 | 5.0 | 1.8 (1.4-2.4) | ||||
| Smoking | Never smoker | 149 | 9.2 | 1.0 | 0.002 | 1.4 (1.1-1.9) | 0.014 |
| Chronic smoker | 288 | 6.1 | 1.5 (1.2-1.9) | ||||
| Treatment | Chemotherapy | 391 | 6.9 | 1.0 | |||
| EGFR inhibitors | 39 | 9.6 | 0.9 (0.6-1.3) | 0.502 | |||
| ALK inhibitors | 9 | 11.2 | 0.6 (0.2-1.5) | 0.251 | |||
| Compassionate based oral TKI therapy | 16 | 3.7 | 1.7 (1.0-2.9) | 0.067 | |||
PFS: Progression-free survival, NSCLC: Non-small cell lung cancer, NOS: Not otherwise specified, ECOG: Eastern cooperative oncology group, EGFR: Epidermal growth factor receptor, ALK: Anaplastic lymphoma receptor tyrosine kinase, TKI’s: Tyrosine kinase inhibitors, HR: Hazard ratio, CI: Confidence interval, SCC: Squamous cell carcinoma, ADC: Adenocarcinoma